{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu H"],"funding":["Fudan University “Star of Tomorrow” Famous Doctor Training Project","Grants from Shanghai Excellent Academic Leader","Shanghai Sailing Program","China National Natural Science Funds"],"pagination":["116"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8935813"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(1)"],"pubmed_abstract":["<h4>Backgrounds</h4>Patients with AICLI constitute a considerable proportion of NO-CLI patients and cannot be treated with surgical or endovascular treatment. Although cell therapy has shown satisfactory results in treating AICLI, research comparing the efficacy of treatment with the 2 kinds of cell products is rare. The aim of this study was to report the 5-year outcomes of a randomized single-blinded noninferiority trial (Number: NCT02089828) on peripheral blood mononuclear cells (PBMNCs) and purified CD34<sup>+</sup> cells (PCCs) transplantation for treating angiitis-induced critical limb ischemia (AICLI).<h4>Methods</h4>A randomized single-blinded non-inferiority trial (Number: NCT02089828) was performed. Fifty patients were randomized 1:1 to the PBMNCs and PCCs groups. Efficacy outcom"],"journal":["Stem cell research & therapy"],"pubmed_title":["The peripheral blood mononuclear cells versus purified CD34<sup>+</sup> cells transplantation in patients with angiitis-induced critical limb ischemia trial: 5-year outcomes and return to work analysis-a randomized single-blinded non-inferiority trial."],"pmcid":["PMC8935813"],"funding_grant_id":["2019","19XD1401200","82000452","81970407","81900426","20YF1406600"],"pubmed_authors":["Liu H","Fang Y","Liu Y","Gu S","Pan T","Fang G","Jiang X","Fu W","Dong Z","Liu P","Wei Z","Chen B"],"additional_accession":[]},"is_claimable":false,"name":"The peripheral blood mononuclear cells versus purified CD34<sup>+</sup> cells transplantation in patients with angiitis-induced critical limb ischemia trial: 5-year outcomes and return to work analysis-a randomized single-blinded non-inferiority trial.","description":"<h4>Backgrounds</h4>Patients with AICLI constitute a considerable proportion of NO-CLI patients and cannot be treated with surgical or endovascular treatment. Although cell therapy has shown satisfactory results in treating AICLI, research comparing the efficacy of treatment with the 2 kinds of cell products is rare. The aim of this study was to report the 5-year outcomes of a randomized single-blinded noninferiority trial (Number: NCT02089828) on peripheral blood mononuclear cells (PBMNCs) and purified CD34<sup>+</sup> cells (PCCs) transplantation for treating angiitis-induced critical limb ischemia (AICLI).<h4>Methods</h4>A randomized single-blinded non-inferiority trial (Number: NCT02089828) was performed. Fifty patients were randomized 1:1 to the PBMNCs and PCCs groups. Efficacy outcom","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-26T22:28:11.686Z","creation":"2024-11-09T02:18:28.094Z"},"accession":"S-EPMC8935813","cross_references":{"pubmed":["35313967"],"doi":["10.1186/s13287-022-02804-4"]}}